Imazodan hydrochloride

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 525274

CAS#: 89198-09-4

Description: Imazodan hydrochloride is a potent and selective type III phosphodiesterase inhibitor.Imazodan hydrochloride is used for the treatment of chronic congestive heart failure.

Chemical Structure

img
Imazodan hydrochloride
CAS# 89198-09-4
Instruction

Theoretical Analysis

MedKoo Cat#: 525274
Name: Imazodan hydrochloride
CAS#: 89198-09-4
Chemical Formula: C13H13ClN4O
Exact Mass: 0.00
Molecular Weight: 276.720
Elemental Analysis: C, 56.42; H, 4.74; Cl, 12.81; N, 20.25; O, 5.78

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Imazodan hydrochloride; Imazodan HCl; CI-914; CI 914; CI914; Imazodan hydrochloride [USAN].

IUPAC/Chemical Name: 3(2H)-Pyridazinone, 4,5-dihydro-6-(4-(1H-imidazol-1-yl)phenyl)-, monohydrochloride

InChi Key: BFIMZKOUNDYWCE-UHFFFAOYSA-N

InChi Code: InChI=1S/C13H12N4O.ClH/c18-13-6-5-12(15-16-13)10-1-3-11(4-2-10)17-8-7-14-9-17;/h1-4,7-9H,5-6H2,(H,16,18);1H

SMILES Code: O=C1CCC(C2=CC=C(N3C=CN=C3)C=C2)=NN1.[H]Cl

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 276.72 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Goldberg AD, Nicklas J, Goldstein S. Effectiveness of imazodan for treatment of chronic congestive heart failure. The Imazodan Research Group. Am J Cardiol. 1991 Sep 1;68(6):631-6. PubMed PMID: 1715125.

2: Allert JA, Adams HR. Inotropic and chronotropic profile of MCI-154: comparison with isoproterenol and imazodan in guinea pig cardiac preparations. J Cardiovasc Pharmacol. 1990 Jul;16(1):59-67. PubMed PMID: 1696667.

3: Jiang YY, Long K, Sheng ML. [Effects of imazodan and dazoxiben on cAMP levels and PGI2 production in cultured bovine aortic endothelial cells]. Zhongguo Yao Li Xue Bao. 1989 Sep;10(5):421-4. Chinese. PubMed PMID: 2559580.

4: Weishaar RE, Kobylarz-Singer D, Klinkefus BA. New mechanisms for positive inotropic agents: focus on the discovery and development of imazodan. Cardiovasc Drugs Ther. 1989 Mar;3(1):29-42. Review. PubMed PMID: 2487522.

5: Geria T, Hong WH, Daly RE. High-performance liquid chromatographic assay of imazodan, methylparaben and propylparaben in imazodan injection. J Chromatogr. 1988 Oct 26;450(3):407-13. PubMed PMID: 3241022.

6: Sircar I, Morrison GC, Burke SE, Skeean R, Weishaar RE. Cardiotonic agents. 6. Synthesis and inotropic activity of 2,4-dihydro-5-[4-(1H-imidazol-1-yl)phenyl]-3H-pyrazol-3-ones: ring-contracted analogues of imazodan (CI-914). J Med Chem. 1987 Oct;30(10):1724-8. PubMed PMID: 3656349.

7: Steffen RP, Eldon CM, Evans DB. The effect of the cardiotonic imazodan (CI-914) on myocardial and peripheral hemodynamics in the anesthetized dog. J Cardiovasc Pharmacol. 1986 May-Jun;8(3):520-6. PubMed PMID: 2425167.